LSTA:NASDAQ
Lisata Therapeutics Inc
US$3.22
arrow_upward
+0.62%(+0.020) 1D
4월 29일, 오후 4시 0분 0초 GMT-4 · USD
search
모든 종목 코드
1D
5D
1M
6M
YTD
1Y
5Y
최대
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoLSTA의 주요 통계 생성 중...
시가
US$3.18
고가
US$3.25
저가
US$3.12
시가총액
2908.40만
평균 거래량
8.41만
거래량
6.17만
52주 최고가
US$5.07
52주 최저가
US$1.81
EPS
-US$1.91
베타
1.10
유통 주식수
903.20만
직원 수
21
뉴스 기사
웹 소스 기반
Stocktwits
·
15분 전
S&P 500, Nasdaq Futures Climb After Mag 7 Earnings Kickoff: MSFT, META, AMZN, GOOG, INTC Stocks In Focus
Simply Wall Street
·
39분 전
Ionis Pharmaceuticals (IONS) Trailing US$381.4m Loss Tests Bullish Profitability Narratives Ahead Of Q1 2026
Investor's Business Daily
·
1시간 전
Tech Futures Rise On Titans' Results And CapEx Plans
프로필
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Lisata Therapeutics Inc에 관한 정보